Helsinn Group, a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, announced that Akynzeo (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn Group has renewed a distribution and licence agreement with Angelini Pharma for the commercialisation of AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries.
Lugano (Switzerland) and Rome (Italy)– May 27, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an international pharmaceutical company, part of the Italian privately-owned multi-business Angelini Industries, that researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health, announce today the signing of the Distribution and Licence Agreement renewal in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic for AULIN® and MESULID® (Nimesulide) for the treatment of acute (short-term) pain.
Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (œHelsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Helsinn closes financing agreement with Oberland Capital
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Lugano, Switzerland, October 18, 2022 - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces that research from an in vitro study of chlormethine gel has been published in the journal Dermatology and Therapy.